- Home
- MDCX vs VTGN Comparison
MDCX vs VTGN Comparison
Compare MDCX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | VTGN |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 9.5M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MDCX | VTGN |
|---|---|---|
| Price | $3.37 | $0.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $225.00 | $1.00 |
| AVG Volume (30 Days) | 2.4M | ★ 18.1M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $33.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.08 | $0.20 |
| 52 Week High | $4.69 | $5.14 |
Technical Indicators
Market Signals| Indicator | MDCX | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 83.66 | 35.06 |
| Support Level | $0.26 | $0.20 |
| Resistance Level | N/A | $0.32 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | 0.37 | -0.01 |
| Stochastic Oscillator | 70.36 | 0.26 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.